Market revenue in 2020 | USD 50.5 million |
Market revenue in 2028 | USD 113.3 million |
Growth rate | 10.6% (CAGR from 2020 to 2028) |
Largest segment | Immunological disorders |
Fastest growing segment | Endocrine & Metabolism Diseases |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Immunological disorders was the largest segment with a revenue share of 12.67% in 2020. Horizon Databook has segmented the Canada rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Canadian Organization Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that are dedicated to management of patients with rare disorders. The agency works with clinicians, researchers, governments, and diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country.
In Canada, 1 out of 12 people has a rare disease. Thus, several framework and initiatives have been introduced over the past years to advance rare disease management in the country. For instance, the Rare Diseases Working Group (RDWG), introduced in 2016.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Canada rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account